Exciting news on ICH GCP E6(R3) is here! Our CEO, Artem Andrianov, returned from the SCOPE Summit with updates on the updated guideline. ICH E6(R3) will incorporate technology advancements while prioritizing participant protection and reliable evidence. Don't miss Artem's thoughts on his experience at the summit. Stay tuned for more updates on ICH E6(R3)!
With the ICH E6(R3) guideline set for approval by October 2024, sponsors face new requirements in risk management, RBQM, and data integrity. Stay compliant and efficient by downloading our free infographic that highlights the key differences between ICH E6(R2) and E6(R3).
Explore the impact of ICH's Q9(R1), Quality Risk Management, guideline on RBQM and clinical trials in our latest blog post. Don't miss our free infographic that simplifies this complex guideline. Enhance your risk strategies today!
Don’t Miss Out! We’re excited to announce that our CEO, Artem Andrianov, will be hosting an exclusive workshop at the 10th Annual Clinical Monitoring and Patient Recruitment Retention (CMPRR) Summit in Barcelona this November!
Building Critical to Quality Trees helps you to translate critical study needs and quality drivers into measurable outcomes and processes. Initially, this Lean Six Sigma approach serves as a business tool based on customer needs. Still, it is a helpful method of implementing Quality by Design in clinical research.
Cyntegrity’s Diabetes RACT helps teams identify key risks early, strengthen data quality, and run safer, smarter diabetes clinical trials.
For oncology study teams: see how ADAMAS applied Cyntegrity’s risk signals to focus QA in a global Phase III trial, supporting earlier actions and inspection readiness.
Cyntegrity at ACDM RBQM 2025: Artem Andrianov & Johann Proeve share insights on CDM evolution, RBQM, and MyRBQM Portal for safer, reliable trials.
Join Cyntegrity at SCOPE 2025 Barcelona, Booth #4, and explore how AI-powered RBQM cuts review cycles by 30% and boosts inspection readiness.
Download our DIA 2025 posters and see how upfront RBQM—applied to rare-disease trials and joint CRF design—sharpens data quality, elevates patient safety, and keeps studies ICH E6(R3)-ready.
